Endothelial Function
Conditions
Keywords
endothelial function, statins, ezetimibe, pleiotropism
Brief summary
* To test the hypothesis that therapy with high dose statin provides endothelial superior benefit to the same cholesterol lowering with low-dose statin combined with ezetimibe. * To test the hypothesis that therapy with high dose statin provides anti-inflammatory effect than the same reduction of cholesterol with low dose of statin plus ezetimibe
Detailed description
Randomized, double-blind, placebo-controlled study. Inclusion Criteria: Obese women with body mass index (BMI)\> 25 kg / m², aged 18 years and LDL-C\> 100 mg / dl For treatment with simvastatin 80 mg, the participant will receive two identical vials, each containing a simvastatin 40 mg. For treatment with the combination simvastatin 10 mg and ezetimibe 10 mg, the participant will receive two identical bottles, one bottle with simvastatin 10 mg, and another bottle with ezetimibe 10mg. In the control group, each participant will receive two identical bottles, each bottle containing inert tablets. Each group with 20 participants. Dependent Variable (Final Primary Outcome): Percentage change vasodilation of brachial artery flow-mediated, after treatment for eight weeks. Covariates: clinical, biochemical markers and ultrasound.
Interventions
DRUGsimvastatin, combined with simvastatin ezetimibe, placebo
simvastatin 80 mg per days or simvastatin 10 mg and ezetimibe 10 mg, over a period of eight weeks, treatment consisted of tablets identical, or placebo
Sponsors
Escola Bahiana de Medicina e Saude Publica
Federal University of Bahia
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Women with body mass index (BMI)\> 25 kg / m² * Aged \> 18 years * LDL-C\> 100 mg / dl
Exclusion criteria
* Previous use of statins, fibrates or ezetimibe * Triglycerides\> 400 mg / dl * Serum creatinine greater than 2.0 md / dl * Elevated liver enzymes, more than one and half times the upper limit of normal * Creatine kinase (CK) levels more than three times the upper limit of normal * Pregnant * Breast-feeding * Heart failure * Psychiatric disorders * Hormone replacement therapy. * The occurrence of recent onset within the last four weeks of treatment with beta-blockers, converting enzyme inhibitor or calcium channel blocker, the intervention should be undertaken after a period of at least four weeks of continuous use. * Acute inflammatory processes in the last month, assessed by clinical history and physical examination (ear, throat, skin lesions or other inflammatory manifestations) as well as reports of chronic diseases such as collagen, or the occurrence of active tuberculosis in the last three months will be excluded from work.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percent change vasodilation of brachial artery flow-mediated, after eight weeks of treatment. | 8 weeks |
Secondary
| Measure | Time frame |
|---|---|
| biochemical markers | 8 weeks |
Countries
Brazil
Contacts
Primary ContactMaristela M Garcia, MD
Backup ContactLuis Claudio L Correia, Phd
Outcome results
None listed